Ieq Capital LLC Purchases Shares of 28,828 Stryker Corporation $SYK

Ieq Capital LLC acquired a new stake in Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 28,828 shares of the medical technology company’s stock, valued at approximately $9,076,000.

Other large investors also recently modified their holdings of the company. Sankala Group LLC acquired a new position in Stryker in the 4th quarter valued at about $26,000. United Financial Planning Group LLC acquired a new stake in Stryker during the third quarter worth approximately $27,000. Godfrey Financial Associates Inc. acquired a new stake in Stryker during the fourth quarter worth approximately $26,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker during the fourth quarter worth approximately $27,000. Finally, Gables Capital Management Inc. acquired a new position in shares of Stryker in the second quarter valued at approximately $25,000. 77.09% of the stock is owned by institutional investors.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 665,370 shares of company stock worth $216,238,501. 4.60% of the stock is currently owned by company insiders.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Stock Up 0.1%

Shares of SYK opened at $329.86 on Monday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The firm’s 50 day moving average is $326.99 and its 200-day moving average is $332.39. The stock has a market capitalization of $126.52 billion, a PE ratio of 34.18, a P/E/G ratio of 2.10 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is currently 36.48%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent research reports. Leerink Partners lowered their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Raymond James Financial set a $370.00 price target on Stryker in a research note on Friday, July 31st. Sanford C. Bernstein set a $410.00 price objective on Stryker in a report on Friday, May 1st. Needham & Company LLC lowered their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, UBS Group started coverage on Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.